Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Market Underperformance

Stock Price Movement and Market Context

On 1 December 2025, Norris Medicines recorded its lowest price in the past year at Rs.14.5. This level represents a substantial drop from its 52-week high of Rs.24.65, indicating a decline of approximately 41%. The stock’s performance today showed a day change of -3.33%, underperforming its sector by 3.02%. Norris Medicines is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.

In contrast, the broader market has shown resilience. The Sensex opened higher at 86,065.92 points, gaining 359.25 points (0.42%) before trading slightly lower at 85,817.40 points (0.13%). The Sensex remains close to its 52-week high of 86,055.86, just 0.28% away, and has experienced a three-week consecutive rise, accumulating a gain of 1.48%. Small-cap stocks have led the market rally, with the BSE Small Cap index advancing by 0.34% on the same day.

Financial Performance and Long-Term Trends

Over the past year, Norris Medicines has generated a return of -26.10%, contrasting with the Sensex’s positive 7.52% return over the same period. The company’s long-term financial indicators reveal subdued growth and profitability. Net sales have shown a negative compound annual growth rate of -2.13% over the last five years, while operating profit has remained flat during this period.

The company’s earnings before interest, depreciation, taxes and amortisation (EBITDA) have been negative, with the latest quarterly PBDIT reported at Rs.-0.49 crore. Profit before tax excluding other income (PBT less OI) also registered a low of Rs.-0.72 crore, and earnings per share (EPS) stood at Rs.-0.73 for the quarter. These figures highlight ongoing pressure on profitability and cash flow generation.

Balance Sheet and Risk Factors

Norris Medicines carries a negative book value, which points to weak long-term fundamental strength. The company’s debt profile shows an average debt-to-equity ratio of zero, indicating limited reliance on external borrowings. However, the negative EBITDA and declining profitability metrics contribute to a riskier valuation compared to its historical averages.

Over the last year, profits have fallen by approximately 71%, further emphasising the challenges faced by the company. The stock’s performance has also lagged behind the BSE500 index over the last three years, one year, and three months, underscoring a pattern of below-par returns in both the near and long term.

Shareholding and Market Position

The majority of Norris Medicines’ shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company operates within the Trading & Distributors sector, which has seen mixed performance relative to broader market indices.

Summary of Recent Developments

The latest quarterly results for Norris Medicines showed flat outcomes, with key profitability indicators at their lowest levels. The company’s PBDIT and PBT less other income figures remain in negative territory, while EPS has also declined to Rs.-0.73. These results reflect ongoing financial pressures amid a challenging market environment.

Despite the broader market’s positive trajectory, Norris Medicines continues to face headwinds that have contributed to its stock price reaching a new 52-week low. The stock’s current valuation and financial metrics suggest a cautious outlook based on recent performance data.

Market Comparison and Sector Performance

While Norris Medicines has struggled, the Sensex and small-cap indices have shown strength. The Sensex’s position near its 52-week high and its bullish moving averages contrast with the stock’s downward trend. The BSE Small Cap index’s gain of 0.34% today highlights pockets of market optimism that have not extended to Norris Medicines.

This divergence emphasises the stock’s relative underperformance within its sector and the broader market context.

Conclusion

Norris Medicines’ stock reaching Rs.14.5 marks a significant milestone as it touches its lowest price point in the past year. The company’s financial data over recent quarters and years illustrates a pattern of subdued growth, negative profitability, and valuation challenges. While the broader market environment remains positive, Norris Medicines continues to face hurdles that have influenced its stock price trajectory.

Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →